Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Bioprocess Validation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Bioprocess Validation Market to Reach $622.6 Million by 2030
The global market for Bioprocess Validation estimated at US$253.5 Million in the year 2022, is projected to reach a revised size of US$622.6 Million by 2030, growing at a CAGR of 11.9% over the analysis period 2022-2030.
Extractables / Leachables Testing Services, one of the segments analyzed in the report, is projected to record 13.1% CAGR and reach US$255.6 Million by the end of the analysis period. Growth in the Integrity Testing Services segment is estimated at 12% CAGR for the next 8-year period. 
The pandemic significantly impacted the bioprocess validation market, altering its trajectory and dynamics. Bioprocess validation, a critical aspect of ensuring product quality and regulatory compliance in biopharmaceutical manufacturing, encompasses various validation processes. The global market outlook for bioprocess validation remains optimistic, with extractables/leachables testing services emerging as the largest segment.
Developed regions currently lead the market, but developing economies show promise for future growth. Competition in the bioprocess validation market is fierce, with key competitors vying for market share, as indicated by the percentage market share breakdown in 2023. Market players worldwide exhibit varying degrees of market presence, categorized as strong, active, niche, or trivial. Recent market activity reflects ongoing developments and strategic maneuvers within the industry.
The U.S. Market is Estimated at $95 Million, While China is Forecast to Grow at 17.3% CAGR
The Bioprocess Validation market in the U.S. is estimated at US$95 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$80.8 Million by the year 2030 trailing a CAGR of 17.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 10.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.5% CAGR.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 385 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $253.5 Million |
| Forecasted Market Value (USD) by 2030 | $622.6 Million |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
MARKET OVERVIEW
- Pandemic Impact on Bioprocess Validation Market
- An Introduction to Bioprocess Validation
- Types of Process Validation
- Global Market Outlook
- Extractables/Leachables Testing Services: The Largest Segment
- Developed Regions Lead, Developing Economies Promise Future Growth
- Competition
- Bioprocess Validation - Global Key Competitors Percentage Market Share in 2023 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
- Recent Market Activity
MARKET TRENDS & DRIVERS
- Rapid Growth in Biopharmaceutical Production and Need to Prevent Product Contamination Necessitate Validation Services
- Global Biopharmaceuticals Market in US$ Billion for the Years 2022, 2024, 2026 and 2028
- Increasing Pharma & Biotech Investments into Drug Development Activities Fuel Need for Bioprocess Validation
- Pharmaceutical R&D Spending Worldwide (USD Billion) for 2015-2025
- Rise of Pharma Contract Manufacturing Present Growth Opportunities for Bioprocess Validation Outsourcing to Emerging Markets
- Global Pharmaceutical Contract Manufacturing Market by Geographic Region for 2021 and 2027
- Biosimilars Gain from Patent Expiry of Major Drugs, Driving Gains for Bioprocess Validation Market
- Strict Safety & Quality Regulations and Compliance with cGMP for Biopharmaceuticals Support Market Growth
- Bioprocessing 4.0: Implications for Bioprocess Validation
- Validation 4.0: Essential for Sciences Industry Progresses towards Digital-First Industry
- Growing Prominence of Paperless Validation in Pharma, Biotech & Medical Devices Industries
- Bioprocess Innovations Direct Focus onto Effective & Clear Validations
- Digital Twins to Support Bioprocess Validation Market Growth
- AI-Enabled System-Led Transformations in Biomanufacturing & Bioprocess Validation
- Artificial Intelligence and Continuous Validation
- Single-Use Disposable Technologies Gain Attention
- Bioprocess Data: Critical for Improving Efficiency of Pharma Developments & Manufacturing Operations
- Advancing Process Analytical Technologies Necessitates Validation
- Process Validation for Viral Vectors: What are the Key Challenges?
- Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
- Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
- Challenges Confronting Bioprocess Validation
FOCUS ON SELECT PLAYERS(Total 50 Featured)
- Almac Group
- Bangalore Biotech Labs Pvt Ltd (Biozeen)
- DOC S.r.l
- Eurofins Scientific SE
- Hangzhou Cobetter Filtration Equipment Co. Ltd.
- Lonza Group AG
- Meissner Filtration Products, Inc.
- Merck KGaA
- Pall Corporation, a subsidiary of Danaher Corporation
- Porvair Plc
- Sartorius AG
- SGS S.A.
- Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/jyrrvo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
